Cabozantinib for kidney cancer in people on dialysis
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies how well cabozantinib works for advanced kidney cancer in people who are already receiving hemodialysis. It aims to see whether the treatment is effective and safe for this specific kidney function group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic kidney cancer confirmed by a pathology report, with clear-cell or papillary type.
- You have already had at least one previous anti-cancer treatment taken throughout the body.
- You are on hemodialysis (dialysis through a machine) for more than 3 months, and it’s been going okay enough to join the study.
- Any side effects from earlier treatments have mostly improved (back to baseline or mild), or are stable/non-significant.
- You are age 18 or older and able to do most daily activities (Karnofsky score 70% or higher).
- Your blood counts and key organ tests (like liver/other labs) are acceptable for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.
This trial looks at how well cabozantinib works in people with advanced kidney cancer that has spread. It focuses on patients who had a quick response or a long response to the drug.
This trial is testing a combination of two drugs, cabozantinib and nivolumab, in people aged 70 or older who have advanced kidney cancer that hasn't been treated yet. The goal is to see if this combination works well and is safe for older patients.
This trial tests a new drug (casdatifan) combined with cabozantinib for advanced clear cell kidney cancer, comparing it to cabozantinib alone. It's for people who haven't taken these specific medicines before and are still in fairly good health.
This Phase 2 study tests a “next-step” cabozantinib strategy for advanced kidney cancer (RCC) after your cancer previously responded to cabozantinib and then progressed. It aims to see if re-using cabozantinib in a planned sequence can control the cancer again with manageable side effects.
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Hear when a new Cancer of Kidney trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.